Irlanda - inglês - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - medroxyprogesterone acetate - suspension for injection - 150 milligram(s)/millilitre - progestogens; medroxyprogesterone

Estados Unidos - inglês - NLM (National Library of Medicine)

teva parenteral medicines, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)] . the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and p

Estados Unidos - inglês - NLM (National Library of Medicine)

pharmacia & upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 104 mg in 0.65 ml - depo-subq provera 104 is indicated in females of reproductive age for: - prevention of pregnancy and - management of endometriosis-associated pain. limitations of use : the use of depo-subq provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of depo-subq provera 104 is contraindicated in the following conditions: - active thrombophlebitis, or current or history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known, suspected, or past malignancy of the breast [see warnings and precautions (5.3)] . - significant liver disease [see warnings and precautions (5.13)] . - known hypersensitivity to medroxyprogesterone acetate or any of the ingredients in depo-subq provera 104 [see warnings and precautions (5.5)] . - undiagnosed vaginal bleeding [

Estados Unidos - inglês - NLM (National Library of Medicine)

eugia us llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)]. - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warn

Quênia - inglês - Pharmacy and Poisons Board

incepta pharmaceuticals ltd. 40, shahid tajuddin ahmed sarani, tejgaon i/a, - medroxyprogesterone acetate - suspension for injection - 150mg/ml - medroxyprogesterone

Canadá - inglês - Health Canada

taro pharmaceuticals inc - medroxyprogesterone acetate - suspension - 150mg - medroxyprogesterone acetate 150mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate - suspension for injection - 150mg/1ml

Estados Unidos - inglês - NLM (National Library of Medicine)

pharmacia & upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of depo-provera ci is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings and precautions (5.10)] . depo-provera ci

Estados Unidos - inglês - NLM (National Library of Medicine)

cardinal health - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 10 mg

Estados Unidos - inglês - NLM (National Library of Medicine)

a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a